Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

77
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
77
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

137
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
137
  1. Home
  3. Relationships Between Pet And Blood Plasma Biomarkers In Corticobasal Syndrome.
  1. Home
  3. Relationships Between Pet And Blood Plasma Biomarkers In Corticobasal Syndrome.

Related Experiment Video

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
08:29

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

16.0K

Relationships between PET and blood plasma biomarkers in corticobasal syndrome.

Neha Atulkumar Singh1, Alla Alnobani2, Jonathan Graff-Radford1

  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|June 17, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Plasma biomarkers phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) can help detect Alzheimer's disease (AD) in corticobasal syndrome (CBS). Neurofilament light (NfL) may indicate CBS regardless of AD pathology.

Keywords:
blood plasma biomarkerscorticobasal syndromepositron emission tomography uptake

More Related Videos

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.9K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.3K

Related Experiment Videos

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
08:29

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

16.0K
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.9K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.3K

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Neurodegenerative Diseases

Background:

  • Corticobasal syndrome (CBS) can be associated with Alzheimer's disease (AD) pathologies.
  • The utility of blood plasma biomarkers for predicting AD in CBS patients remains largely unknown.
  • Positron emission tomography (PET) is a key tool for confirming AD biomarkers.

Purpose of the Study:

  • To investigate the effectiveness of plasma biomarkers in identifying AD pathology in individuals with CBS.
  • To compare plasma biomarker concentrations between CBS patients with and without amyloid-beta (Aβ) positivity.
  • To explore the correlation between plasma biomarkers and PET imaging results.

Main Methods:

  • A cohort of 18 CBS patients (8 Aβ+, 10 Aβ-) and 8 cognitively unimpaired (CU) controls underwent PET imaging and plasma analysis.
  • Plasma concentrations were analyzed and compared using statistical tests (Kruskal-Wallis).
  • Spearman correlations were used to assess relationships between plasma biomarkers and PET uptake.

    • Main Results:

    • CBS patients with Aβ+ pathology showed reduced Aβ42/40 ratio and elevated plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).
    • CBS patients with Aβ- pathology had elevated NfL concentrations compared to controls.
    • Plasma p-tau181 and GFAP levels differentiated between CBS Aβ- and CBS Aβ+ groups and correlated positively with Aβ and tau PET uptake.

    Conclusions:

    • Plasma p-tau181 and GFAP are valuable biomarkers for detecting AD in patients with CBS.
    • Plasma NfL may serve as a general biomarker for CBS, irrespective of the underlying AD pathology.
    • These findings highlight the potential of blood-based biomarkers for improved diagnosis and management of CBS.